Agreement to Develop Long-Acting Rilpivirine as PrEP
On 25 September 2013, Janssen announced that it had signed a license agreement with international nonprofit health organisation PATH for early stage research to develop a long acting depot formulation of rilpivirine as a potential pre-exposure prophylaxis (PrEP) against HIV.1
PATH is planning to collaborate with partners including the HIV Prevention Trials Network for future research for these initial phase 2 studies, and this initiative is funded by the Bill & Melinda Gates Foundation.2
Rilpivirine is an NNRTI currently licensed as an oral drug in ARV treatment-naive adults with a viral load less than or equal to 100,000 copies/mL and is coformulated with tenofovir/FTC in the fixed dose combination Eviplera (Edurant in the U.S.).
Links to other websites are current at date of posting but not maintained.
This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)